CD8A and neoplasm: Furthermore, the patients with a high CD8 + mTILs/CD68 + TAMs ratio gained a major benefit from adjuvant trastuzumab, suggesting that the inflammatory conditions in the tumor microenvironment may influence the efficacy of trastuzumab, but further studies addressing this question are needed.